Login / Signup

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers.

Angela LamarcaSalvatore GaldyJorge BarriusoSharzad MoghadamElizabeth BeckettJane RoganAlison BackenCatherine BillingtonMairéad G McNamaraRichard A HubnerAngela CramerJuan W Valle
Published in: PloS one (2018)
A significant subset of patients with BTC expressed HER3. Inhibition of HER3 warrants further investigation. A better understanding of the downstream effects of HER3 in BTC requires further mechanistic investigations to identify new biomarkers and improve patient selection for future clinical trials.
Keyphrases
  • clinical trial
  • case report
  • current status
  • randomized controlled trial
  • risk assessment
  • climate change
  • study protocol
  • double blind
  • childhood cancer
  • placebo controlled